1-18 of 18
Alfred H. Schinkel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 6322: The role of multidrug efflux transporters and CYP3A in the pharmacokinetics and tissue distribution of abemaciclib and its active metabolites

Alejandra Martinez Chavez, Matthijs M. Tibben, Maria C. Lebre, Hilde Rosing, Jos H. Beijnen, Alfred H. Schinkel
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 6322.
https://doi.org/10.1158/1538-7445.AM2020-6322
Published: 15 August 2020
View article titled, Abstract 6322: The role of multidrug efflux transporters and CYP3A in the pharmacokinetics and tissue distribution of abemaciclib and its active metabolites
Journal Articles

Abstract 1268: The impact of P-glycoprotein, breast cancer resistance protein and CYP3A on pharmacokinetics and metabolism of galunisertib

Wenlong Li, Matthijs Tibben, Yaogeng Wang, Maria C. Lebre, Hilde Rosing, Jos H. Beijnen, Alfred H. Schinkel
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1268.
https://doi.org/10.1158/1538-7445.AM2019-1268
Published: 01 July 2019
View article titled, Abstract 1268: The impact of P-glycoprotein, breast cancer resistance protein and CYP3A on pharmacokinetics and metabolism of galunisertib
Journal Articles

Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b

Aksana Vasilyeva, Selvi Durmus, Lie Li, Els Wagenaar, Shuiying Hu, Alice A. Gibson, John C. Panetta, Sridhar Mani, Alex Sparreboom, Sharyn D. Baker, Alfred H. Schinkel
Journal: Cancer Research
Cancer Res (2015) 75 (13): 2729–2736.
https://doi.org/10.1158/0008-5472.CAN-15-0280
Published: 30 June 2015
View article titled, Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b
Open the PDF for Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b in another window
Includes: Supplementary data
Journal Articles

Abstract 4419: The role of ABC transporters in PhIP-induced colon carcinogenesis

Selvi Durmus, M.A. van der Valk, S.F. Teunissen, Els Wagenaar, Jos Beijnen, Alfred H. Schinkel
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 4419.
https://doi.org/10.1158/1538-7445.AM2012-4419
Published: 15 April 2012
View article titled, Abstract 4419: The role of ABC transporters in PhIP-induced colon carcinogenesis
Journal Articles

Abstract 1518: P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) limit sunitinib brain accumulation which can be enhanced by oral elacridar treatment

Seng Chuan Tang, Jurjen S. Lagas, Nienke Lankheet, Hilde Rosing, Jos H. Beijnen, Alfred H. Schinkel
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 1518.
https://doi.org/10.1158/1538-7445.AM10-1518
Published: 15 April 2010
View article titled, Abstract 1518: P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) limit sunitinib brain accumulation which can be enhanced by oral elacridar treatment
Journal Articles

Absence of Both Cytochrome P450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity

Robert A.B. van Waterschoot, Jurjen S. Lagas, Els Wagenaar, Cornelia M.M. van der Kruijssen, Antonius E. van Herwaarden, Ji-Ying Song, Rogier W. Rooswinkel, Olaf van Tellingen, Hilde Rosing, Jos H. Beijnen, Alfred H. Schinkel
Journal: Cancer Research
Cancer Res (2009) 69 (23): 8996–9002.
https://doi.org/10.1158/0008-5472.CAN-09-2915
Published: 30 November 2009
View article titled, Absence of Both Cytochrome <em>P</em>450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity
Open the PDF for Absence of Both Cytochrome <em>P</em>450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity in another window
Includes: Supplementary data
Journal Articles

ABC- transporter studies of Gimatecan (7-t-butoxyiminomethylcamptothecin) in comparison to topotecan

Serena Marchetti, Roos Oostendorp, Dick Pluim, Olaf Van Tellingen, Alfred H. Schinkel, Richard Versace, Jos H. Beijnen, Roberto Mazzanti, Jan H. Schellens
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 145.
Published: 15 April 2006
View article titled, ABC- transporter studies of Gimatecan (7-t-butoxyiminomethylcamptothecin) in comparison to topotecan
Journal Articles

Functions of the ABC transporter breast cancer resistance protein (BCRP/ABCG2)

Alfred H. Schinkel
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1475–1476.
Published: 01 May 2005
View article titled, Functions of the ABC transporter breast cancer resistance protein (BCRP/ABCG2)
Journal Articles

The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients

Pauline Breedveld, Dick Pluim, Greta Cipriani, Peter Wielinga, Olaf van Tellingen, Alfred H. Schinkel, Jan H.M. Schellens
Journal: Cancer Research
Cancer Res (2005) 65 (7): 2577–2582.
https://doi.org/10.1158/0008-5472.CAN-04-2416
Published: 01 April 2005
View article titled, The Effect of Bcrp1 (Abcg2) on the <em>In vivo</em> Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients
Open the PDF for The Effect of Bcrp1 (Abcg2) on the <em>In vivo</em> Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients in another window
Journal Articles

Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions

Pauline Breedveld, Noam Zelcer, Dick Pluim, Özgür Sönmezer, Matthijs M. Tibben, Jos H. Beijnen, Alfred H. Schinkel, Olaf van Tellingen, Piet Borst, Jan H. M. Schellens
Journal: Cancer Research
Cancer Res (2004) 64 (16): 5804–5811.
https://doi.org/10.1158/0008-5472.CAN-03-4062
Published: 16 August 2004
View article titled, Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: <subtitle>Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions</subtitle>
Open the PDF for Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: <subtitle>Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions</subtitle> in another window
Journal Articles

Mice deficient for the breast cancer resistance protein (Bcrp1/Abcg2): Biological and pharmacological implications.

Johan W. Jonker, Ellen Bolscher, Els Wagenaar, Trevor C. Dale, Alfred H. Schinkel
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 567–568.
Published: 01 April 2004
View article titled, Mice deficient for the breast cancer resistance protein (Bcrp1/Abcg2): Biological and pharmacological implications.
Journal Articles

The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Restricts Exposure to the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine

Antonius E. van Herwaarden, Johan W. Jonker, Els Wagenaar, Remco F. Brinkhuis, Jan H. M. Schellens, Jos H. Beijnen, Alfred H. Schinkel
Journal: Cancer Research
Cancer Res (2003) 63 (19): 6447–6452.
Published: 14 October 2003
View article titled, The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Restricts Exposure to the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
Open the PDF for The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Restricts Exposure to the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in another window
Journal Articles

Mouse Breast Cancer Resistance Protein (Bcrp1/Abcg2) Mediates Etoposide Resistance and Transport, but Etoposide Oral Availability Is Limited Primarily by P-glycoprotein

John D. Allen, Sonja C. van Dort, Marije Buitelaar, Olaf van Tellingen, Alfred H. Schinkel
Journal: Cancer Research
Cancer Res (2003) 63 (6): 1339–1344.
Published: 15 March 2003
View article titled, Mouse Breast Cancer Resistance Protein (Bcrp1/Abcg2) Mediates Etoposide Resistance and Transport, but Etoposide Oral Availability Is Limited Primarily by P-glycoprotein
Open the PDF for Mouse Breast Cancer Resistance Protein (Bcrp1/Abcg2) Mediates Etoposide Resistance and Transport, but Etoposide Oral Availability Is Limited Primarily by P-glycoprotein in another window
Journal Articles

A Mutation Hot Spot in the Bcrp1 (Abcg2) Multidrug Transporter in Mouse Cell Lines Selected for Doxorubicin Resistance

John D. Allen, Sonja C. Jackson, Alfred H. Schinkel
Journal: Cancer Research
Cancer Res (2002) 62 (8): 2294–2299.
Published: 01 April 2002
View article titled, A Mutation Hot Spot in the Bcrp1 (Abcg2) Multidrug Transporter in Mouse Cell Lines Selected for Doxorubicin Resistance
Open the PDF for A Mutation Hot Spot in the Bcrp1 (Abcg2) Multidrug Transporter in Mouse Cell Lines Selected for Doxorubicin Resistance in another window
Journal Articles

Subcellular Localization and Distribution of the Breast Cancer Resistance Protein Transporter in Normal Human Tissues

Marc Maliepaard, George L. Scheffer, Ian F. Faneyte, Margôt A. van Gastelen, Adriana C. L. M. Pijnenborg, Alfred H. Schinkel, Marc J. van de Vijver, Rik J. Scheper, Jan H. M. Schellens
Journal: Cancer Research
Cancer Res (2001) 61 (8): 3458–3464.
Published: 15 April 2001
View article titled, Subcellular Localization and Distribution of the Breast Cancer Resistance Protein Transporter in Normal Human Tissues
Open the PDF for Subcellular Localization and Distribution of the Breast Cancer Resistance Protein Transporter in Normal Human Tissues in another window
Journal Articles

Extensive Contribution of the Multidrug Transporters P-Glycoprotein and Mrp1 to Basal Drug Resistance

John D. Allen, Remco F. Brinkhuis, Liesbeth van Deemter, Jan Wijnholds, Alfred H. Schinkel
Journal: Cancer Research
Cancer Res (2000) 60 (20): 5761–5766.
Published: 15 October 2000
View article titled, Extensive Contribution of the Multidrug Transporters P-Glycoprotein and Mrp1 to Basal Drug Resistance
Open the PDF for Extensive Contribution of the Multidrug Transporters P-Glycoprotein and Mrp1 to Basal Drug Resistance in another window
Journal Articles

The Mouse Bcrp1/Mxr/Abcp Gene: Amplification and Overexpression in Cell Lines Selected for Resistance to Topotecan, Mitoxantrone, or Doxorubicin

John D. Allen, Remco F. Brinkhuis, Jan Wijnholds, Alfred H. Schinkel
Journal: Cancer Research
Cancer Res (1999) 59 (17): 4237–4241.
Published: 01 September 1999
View article titled, The Mouse <em>Bcrp1/Mxr/Abcp</em> Gene: <subtitle>Amplification and Overexpression in Cell Lines Selected for Resistance to Topotecan, Mitoxantrone, or Doxorubicin</subtitle>
Open the PDF for The Mouse <em>Bcrp1/Mxr/Abcp</em> Gene: <subtitle>Amplification and Overexpression in Cell Lines Selected for Resistance to Topotecan, Mitoxantrone, or Doxorubicin</subtitle> in another window
Journal Articles

Characterization of the Human MDR3 P-Glycoprotein and Its Recognition by P-Glycoprotein-specific Monoclonal Antibodies

Alfred H. Schinkel, Marjo E. M. Roelofs, Piet Borst
Journal: Cancer Research
Cancer Res (1991) 51 (10): 2628–2635.
Published: 01 May 1991
View article titled, Characterization of the Human <em>MDR</em>3 P-Glycoprotein and Its Recognition by P-Glycoprotein-specific Monoclonal Antibodies
Open the PDF for Characterization of the Human <em>MDR</em>3 P-Glycoprotein and Its Recognition by P-Glycoprotein-specific Monoclonal Antibodies in another window